Celltrion files IND for Phase 3 study of Actemra biosimilar in Poland
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Celltrion’s biosimilar codenamed CT-P47 is being developed in two formulations – intravenous and subcutaneous – like its reference drug from Roche, which is widely used to treat rheumatoid arthritis (RA) across the world.
The randomized, double-blind, and active-controlled study will enroll a subset of 448 RA patients in Europe to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of CT-P47 for 13 months, the Korean drug giant said in a regulatory filing on Tuesday.
The company said it aims to file a new drug application (NDA) for CT-P47 in the first half of 2024 based on the pivotal study.
Celltrion shares gained 1.06 percent to trade at 142,500 won ($112) on Tuesday.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- DSME’s loss widens in Q1 on year to $368 mn from material cost hikes - Pulse by Maeil Business News Korea
- SK ecoplant reports on-year fall in sales, OP for Q1 in its first IFRS-based filing - Pulse by Maeil Business News Korea
- Hypertension cases nearly double in last 14 years in S. Korea - Pulse by Maeil Business News Korea
- Hyundai, Kia’s Russian operations suffer plunge in utilization rate, sales in Q1 - Pulse by Maeil Business News Korea
- Samsung Electronics adds Qualcomm to its top 5 client list in Q1 - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 전세 대란 돌파구는 ‘로또 분양’, 강동 그란츠·마포자이힐 눈길 [불황에 강한 명품 아파트]
- ‘버닝썬’ 멤버 출소 후 뭐하나 했더니…“승리는 사업, 정준영은 이민 준비”[MK★이슈] - MK스
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이